Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 20
Go back to Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 20| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 197.19 -2.52 (1.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.71 | 52 Week High | $333.65 | |||
| Open | $198.88 | 52 Week Low | $223.02 | |||
| Day High | $201.22 | P/E | 25.25 | |||
| Day Low | $197.01 | EPS | $7.81 | |||
| Volume | 1,146,494 | |||||
